PT-141
Also known as Bremelanotide, Vyleesi
An FDA-approved melanocortin receptor agonist for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.
Regulatory Pathway
Dosing Protocol
Typical Dose
1.75 mg as needed
Frequency
As needed, maximum 8 doses per month
Duration
45 minutes before activity, 1-2 hours before sexual activity
Timing & Administration
Administer via Subcutaneous injection (autoinjector available). Frequency: As needed, maximum 8 doses per month.
Popular Uses
Mechanism of Action
Activates melanocortin receptors, particularly MC4R in the central nervous system. Unlike PDE5 inhibitors that work on blood flow, PT-141 works through the brain's sexual arousal pathways.
Research Summary
Evidence level: fda approved. Clinical status: FDA Approved - HSDD in premenopausal women (June 2019).
Side Effects & Safety
Important Warnings
- Monitor blood pressure
- Skin hyperpigmentation with frequent use.
References
No references available.
Related Peptides
Browse all →A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.
View profileA synthetic analog of alpha-melanocyte stimulating hormone (α-MSH). Known for inducing skin tanning and having effects on libido and sexual function.
View profileA synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects.
View profile